Phreesia 경영진
경영진 기준 점검 3/4
Phreesia CEO는 Chaim Indig, Jan2005 에 임명되었습니다 의 임기는 21.42 년입니다. 총 연간 보상은 $8.26M, 6.2% 급여 및 93.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $13.68M 가치에 해당하는 회사 주식의 2.32% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.3 년과 18.7 년입니다.
핵심 정보
Chaim Indig
최고경영자
US$8.3m
총 보수
| CEO 급여 비율 | 6.23% |
| CEO 재임 기간 | 21.4yrs |
| CEO 지분 보유율 | 2.3% |
| 경영진 평균 재임 기간 | 3.3yrs |
| 이사회 평균 재임 기간 | 18.7yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 01
PHR: Cost Discipline And Higher Margins Will Support Multiple Recovery
Analysts have reduced their average price target for Phreesia by about $1, to roughly $14. Lower revenue growth expectations and multiple downgrades related to growth visibility and competitive pressures are only partly offset by improving profit margin assumptions and a lower projected P/E.내러티브 업데이트 • May 17
PHR: Post Reset Execution On Profitability And Intake Reach Will Support Multiple
Analysts have trimmed their fair value estimate for Phreesia from about $16.17 to $15.39 and lowered the future P/E assumption, reflecting a broad reset in price targets as firms point to slowing digital advertising growth and rising competition. Analyst Commentary Recent research points to a sharp reset in expectations for Phreesia, with multiple firms cutting price targets and, in several cases, downgrading ratings.내러티브 업데이트 • Apr 24
PHR: Post Guidance Reset Execution On Profitability And Intake Reach Will Support Multiple
The updated analyst price target for Phreesia reflects a modest downward adjustment of around $0.28, with analysts pointing to slightly lower assumptions for revenue growth, profit margin, and future P/E, along with a small change in the discount rate. Analyst Commentary Recent research updates on Phreesia have been concentrated on lowering price targets and, in several cases, revising ratings, which points to a clear reset in expectations around growth, profitability, and execution risk.내러티브 업데이트 • Apr 10
PHR: Profitability Focus And Intake Reach Will Support Post Guidance Reset Multiple Resilience
Analysts have reduced their average price target on Phreesia to reflect a lower fair value estimate of about $16.44, down from roughly $27.89. They cited more conservative assumptions for revenue growth, profit margins and future P/E multiples after a broad wave of target cuts and downgrades from multiple firms.Seeking Alpha • Apr 07
Phreesia: Market Delivers A Resounding Vote Of No Confidence (Rating Downgrade)
Summary Phreesia is downgraded from buy to hold after plunging to all-time lows post-Q4 2026, driven by reduced revenue guidance and significant market headwinds. PHR cut FY2027 revenue guidance by 6.7% at the midpoint and now expects only low single-digit revenue per AHSC growth, signaling stalling momentum post-AccessOne acquisition. Despite record free cash flow and maintained adjusted EBITDA guidance, margin protection claims lack specificity amid rising stock-based compensation and upcoming AccessOne investments. Valuation is at 1.0x sales TTM, but with growth stalled and market confidence lost, PHR is now a 'prove it' stock before any upgrade consideration. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 26
PHR: Profitability Focus And Intake Reach Will Support Future Multiple Resilience
Analyst price targets on Phreesia have been trimmed by a few dollars to around the mid $20s, as analysts factor in slightly lower revenue growth and profit margin assumptions while still using a relatively high future P/E of about 37x. Analyst Commentary Recent Street research on Phreesia has centered on fine tuning price targets and reassessing how much investors should pay for the company’s earnings profile, rather than making wholesale shifts in views on the business itself.내러티브 업데이트 • Mar 11
PHR: Profitability Pivot And Intake Network Breadth Will Support Future Margin Expansion
Analysts have trimmed their average price targets on Phreesia by roughly $5 to the mid $20s, reflecting a mix of caution after a challenging period for health tech stocks and continued confidence in the company’s profitability pivot and patient intake platform. Analyst Commentary Recent Street research on Phreesia clusters around a common theme, lower price targets but generally constructive views on the company’s execution and path to profitability.내러티브 업데이트 • Feb 24
PHR: Profitability Pivot And AccessOne Integration Will Drive Future Margin Expansion
The updated analyst price target for Phreesia reflects a modest trim of fair value to about $28.05, as analysts recalibrate their models following a series of target cuts to the $24 to $30 range. They continue to cite the company’s profitability pivot and patient intake platform scale as key parts of the long-term thesis.내러티브 업데이트 • Feb 10
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts have nudged their price targets on Phreesia slightly lower, trimming fair value estimates by about $0.32 to reflect modestly updated assumptions on discount rates, margins, and future P/E. At the same time, recent research highlights both reduced targets in health tech and continued optimism around the company’s patient intake and payments platform.내러티브 업데이트 • Jan 26
PHR: Profitability Pivot And AccessOne Synergies Will Support Future EBITDA Improvement
Analysts have nudged their fair value estimate for Phreesia slightly lower to about $28.63 per share, reflecting modestly softer assumptions for revenue growth, profit margins, and future P/E multiples following a series of recent price target cuts and fresh coverage initiations. Analyst Commentary Recent research paints a mixed picture for Phreesia, with several firms trimming price targets while others initiate or resume positive ratings.내러티브 업데이트 • Jan 12
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts trimmed their fair value estimate for Phreesia to about $29.16 from $29.82 and lowered future P/E assumptions, pointing to reduced Street price targets in the mid $20s, even as research notes highlight the company’s profitability focus, margin progress, and reach across U.S. patient visits. Analyst Commentary Street research on Phreesia is mixed, with several firms trimming price targets while still highlighting profitability efforts, margin progress, and the scale of the platform across U.S. patient visits.내러티브 업데이트 • Dec 24
PHR: Cross Sell And AccessOne Integration Will Drive Future EBITDA Expansion
Narrative Update Analysts have modestly trimmed their price target on Phreesia to approximately $29.82 from about $32.12 per share, reflecting slightly lower assumptions for revenue growth and profit margins even as they highlight the company’s growing cross-sell traction, long-term lift from the pending AccessOne acquisition, and potential for significant operating leverage to drive EBITDA growth in the high-20s to low-30s percentage range. Analyst Commentary Analysts generally view Phreesia positively, with recent coverage initiating the stock with an Outperform rating and a price target modestly above current levels, citing a strengthening growth and profitability profile.내러티브 업데이트 • Dec 10
PHR: Cross Selling Momentum Will Drive Stronger Long Term EBITDA Expansion
Analysts have modestly reduced their price target on Phreesia from $33.73 to $32.12 per share, citing expectations for stronger long term EBITDA growth supported by cross selling traction and operating leverage, as well as incremental upside from the pending AccessOne acquisition. Analyst Commentary Analysts highlight that Phreesia's current valuation reflects confidence in its ability to execute on growth initiatives while expanding margins, but they also caution that the shares already price in a meaningful portion of the long term opportunity.분석 기사 • Sep 27
Phreesia, Inc.'s (NYSE:PHR) 26% Cheaper Price Remains In Tune With Revenues
Phreesia, Inc. ( NYSE:PHR ) shareholders won't be pleased to see that the share price has had a very rough month...내러티브 업데이트 • Sep 06
AI Integration And Digital Adoption Will Expand Healthcare Services
Phreesia’s price target increased to $33.73 as analysts responded positively to solid Q2 results, upwardly revised FY26 EBITDA guidance, strategic product launches, and the AccessOne acquisition—despite valuation concerns—supporting a strong double-digit growth outlook and margin expansion. Analyst Commentary Solid Q2 results, with revenues in line and adjusted EBITDA ahead of consensus; company raised FY26 EBITDA guidance driven by effective expense management.새로운 내러티브 • May 27
Digital Healthcare Tools Will Expand Market Reach
Expanding digital adoption and data-driven solutions are driving operational efficiency, deeper client relationships, and long-term recurring revenue growth.분석 기사 • Apr 29
Revenues Tell The Story For Phreesia, Inc. (NYSE:PHR)
There wouldn't be many who think Phreesia, Inc.'s ( NYSE:PHR ) price-to-sales (or "P/S") ratio of 3.4x is worth a...분석 기사 • Mar 07
Why Phreesia, Inc. (NYSE:PHR) Could Be Worth Watching
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...분석 기사 • Feb 14
Phreesia (NYSE:PHR) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Dec 27
Phreesia, Inc.'s (NYSE:PHR) Shares Climb 27% But Its Business Is Yet to Catch Up
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Dec 12
Phreesia Has Turned The Corner, Can It Continue To Mend?
Summary Phreesia’s Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue estimates, while fiscal 2026 projects slower revenue growth but significant EBITDA improvement. Strong cash flow and disciplined expense management are encouraging, with the company maintaining positive cash flows and holding $82M in cash. Despite current trading challenges, Phreesia’s innovative healthcare solutions and partnerships position it well for future growth and potential valuation recovery. Read the full article on Seeking Alpha분석 기사 • Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues
With a price-to-sales (or "P/S") ratio of 3.1x Phreesia, Inc. ( NYSE:PHR ) may be sending bearish signals at the...분석 기사 • Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results
Phreesia, Inc. ( NYSE:PHR ) last week reported its latest second-quarter results, which makes it a good time for...Seeking Alpha • Sep 05
Phreesia: Remain Bullish Given The Healthy Growth Outlook
Summary I maintain a buy rating for PHR, driven by strong client growth, solid revenue outlook, and increasing transaction sizes in the pipeline. PHR's 2Q25 results show 19% y/y revenue growth and improved profitability, with positive EBITDA and FCF, indicating strong financial health. Despite a slight decline in revenue per AHSC, larger client acquisitions and increased transaction sizes support my 20% growth expectation. Read the full article on Seeking Alpha분석 기사 • Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jun 06
Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve
Summary Phreesia's revenue grew 20.7% year-over-year, with subscription revenue growing 23.4% and payment processing revenue growing 11.6%. The company added 103 new clients in the quarter, beating guidance, and expects to add around 100 more in the next quarter. Phreesia's focus on profitability is showing positive results, with EBITDA margin expanding and guidance suggesting further improvement. Read the full article on Seeking Alpha분석 기사 • May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...분석 기사 • May 03
Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Phreesia fair value estimate is US$36.24 Current share price...분석 기사 • Apr 12
At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it received a lot of attention from a substantial...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Apr 30 2026 | n/a | n/a | US$9m |
| Jan 31 2026 | US$8m | US$515k | US$2m |
| Oct 31 2025 | n/a | n/a | -US$5m |
| Jul 31 2025 | n/a | n/a | -US$24m |
| Apr 30 2025 | n/a | n/a | -US$43m |
| Jan 31 2025 | n/a | n/a | -US$59m |
| Oct 31 2024 | n/a | n/a | -US$83m |
| Jul 31 2024 | n/a | n/a | -US$100m |
| Apr 30 2024 | n/a | n/a | -US$119m |
| Jan 31 2024 | US$8m | US$495k | -US$137m |
| Oct 31 2023 | n/a | n/a | -US$144m |
| Jul 31 2023 | n/a | n/a | -US$152m |
| Apr 30 2023 | n/a | n/a | -US$162m |
| Jan 31 2023 | US$8m | US$515k | -US$176m |
| Oct 31 2022 | n/a | n/a | -US$185m |
| Jul 31 2022 | n/a | n/a | -US$181m |
| Apr 30 2022 | n/a | n/a | -US$158m |
| Jan 31 2022 | US$9m | US$515k | -US$118m |
| Oct 31 2021 | n/a | n/a | -US$80m |
| Jul 31 2021 | n/a | n/a | -US$50m |
| Apr 30 2021 | n/a | n/a | -US$32m |
| Jan 31 2021 | US$6m | US$419k | -US$27m |
| Oct 31 2020 | n/a | n/a | -US$23m |
| Jul 31 2020 | n/a | n/a | -US$19m |
| Apr 30 2020 | n/a | n/a | -US$83m |
| Jan 31 2020 | US$10m | US$346k | -US$91m |
보상 대 시장: Chaim의 총 보수(USD8.26M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.61M)보다 높습니다.
보상과 수익: Chaim의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Chaim Indig (46 yo)
21.4yrs
재임 기간
US$8,262,693
보수
Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | US$8.26m | 2.32% $ 13.7m | |
| Co-Founder & President of Provider Solutions | 21.4yrs | US$3.66m | 1.14% $ 6.7m | |
| Chief Financial Officer | 3.3yrs | US$3.66m | 0.031% $ 185.6k | |
| General Counsel & Secretary | 5.8yrs | US$2.65m | 0.077% $ 452.4k | |
| President of Network Solutions | 7.3yrs | US$3.63m | 0.15% $ 908.9k | |
| Senior VP & Chief Accounting Officer | less than a year | 데이터 없음 | 0.039% $ 228.1k | |
| Chief Technology Officer | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Marketing | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Human Resources | 16.2yrs | 데이터 없음 | 0.27% $ 1.6m | |
| Chief Information Security Officer | 1.4yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Product | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Provider Sales | less than a year | 데이터 없음 | 데이터 없음 |
3.3yrs
평균 재임 기간
46yo
평균 나이
경험이 풍부한 관리: PHR의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | US$8.26m | 2.32% $ 13.7m | |
| Board Observer | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 18.7yrs | US$222.43k | 0.11% $ 626.0k | |
| Independent Chairman | 21.4yrs | US$359.99k | 0.31% $ 1.8m | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.1yrs | US$247.43k | 0.076% $ 446.6k | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.7yrs | US$234.99k | 0.0099% $ 58.3k |
18.7yrs
평균 재임 기간
64yo
평균 나이
경험이 풍부한 이사회: PHR의 이사회는 노련하고 경험이 풍부합니다(평균 재임 18.7 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/07 00:11 |
| 종가 | 2026/06/05 00:00 |
| 수익 | 2026/04/30 |
| 연간 수익 | 2026/01/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Phreesia, Inc.는 23명의 분석가가 다루고 있습니다. 이 중 19명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Joseph Vruwink | Baird |
| Glen Santangelo | Barclays |
| Zhilin Long | Berenberg |